

| | |
|--------------|--|
| DATE: | 22 July 2024 |
| TO: | All Healthcare Professionals in North Zone, Edmonton Zone, Central Zone (sites who refer samples to Edmonton for analysis) |
| FROM: | Clinical Biochemistry, Alberta Precision Laboratories (APL) |
| RE: | Changes to Xylazine Reporting for UODP and UGTP |

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message

- Effective August 1, 2024, xylazine will be a reportable component of the Urine Opioid Dependency Panel (UODP) with a cutoff concentration of 5 ng/mL. The xylazine cutoff concentration for the Urine General Toxicology Panel (UGTP) will be lowered to 5 ng/mL.

Background

- Xylazine is currently only available in the Urine General Toxicology Panel, with a cutoff concentration of 50 ng/mL.

How this will impact you

- The addition of xylazine to UODP and the lower cutoff concentration means that more patients could be identified as having detectable xylazine.

Action Required

- Be aware of reporting changes to the Urine Opioid Dependency Panel and Urine General Toxicology Panel.

Effective August 1, 2024

Questions/Concerns

- Dr. Penny Colbourne, Clinical Toxicologist, North Sector, APL, 780-407-4729, penny.colbourne@aplabs.ca
- Dr. Dylan Thomas, Clinical Toxicologist, North Sector, APL, 780-407-8444, dylan.thomas@aplabs.ca

Approved by

- Dr. Kareena Schnabl, Section Chief Biochemistry, North Sector, APL
- Dr. Michael Mengel, North Sector Medical Director, APL

Effective September 1, 2023, APL has become the sole provider of all public lab services in Alberta. As a result, community lab services formally provided by DynaLIFE Medical Labs will become the responsibility of Alberta Precision Labs (APL). This change impacts all zones.